1. Home
  2. NEXI

NEXI

NexImmune Inc.

Logo NexImmune Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 12:25pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Founded: 2011 Country:
United States
United States
Employees: N/A City: GAITHERSBURG
Market Cap: 4.6M IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 643.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -30.82 EPS Growth: N/A
52 Week Low/High: $1.25 - $28.70 Next Earning Date: 04-16-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: